US Foods

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

Retrieved on: 
Thursday, October 19, 2023
FDA, Isavuconazonium, Gravitas, US Foods, Safety, I.V. (song), QIDP, LR, USD, Therapy, Patient, Infection, Pharmaceutical industry, Aspergillus, Allschwil

David Veitch, Chief Executive Officer of Basilea, stated: “This is the first transaction in the implementation of our strategy to expand our clinical-stage anti-infectives pipeline and to complement our portfolio of marketed products, Cresemba and Zevtera.

Key Points: 
  • David Veitch, Chief Executive Officer of Basilea, stated: “This is the first transaction in the implementation of our strategy to expand our clinical-stage anti-infectives pipeline and to complement our portfolio of marketed products, Cresemba and Zevtera.
  • Based on its novel mechanism of action which results in rapid fungicidal activity in vitro, BAL2062 could become a valuable treatment option against difficult-to-treat invasive mold infections.
  • To define the optimal positioning and the most efficient clinical development path, we will initiate a focused preclinical profiling program.
  • In addition, Basilea will pay tiered royalties on sales starting in the low single-digit percentage range, going to the mid-single-digit percentage range.

Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients

Retrieved on: 
Wednesday, October 18, 2023
GMG, FDA, UCB, University, MDA, Muscular Dystrophy Association, Physician, US Foods, News, Pediatrics, Eyelid, Disease, Acetylcholine receptor, Patient, Doctor of Philosophy, Associate, Agonal respiration, Pharmaceutical industry

New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Key Points: 
  • New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
  • Zilucoplan is the first once-daily subcutaneous, targeted C5 complement inhibitor for gMG, and it is the only once-daily gMG-target therapy for self-administration.
  • "The recent approval of zilucoplan is great news for people living with gMG,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
  • “This is the second gMG therapy out of UCB that has achieved FDA approval this year, providing patients and physicians with important options.

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Wednesday, October 25, 2023
Seniors, Biotechnology, Pharmaceutical, Health, FDA, Infectious Diseases, Consumer, Clinical Trials, RSV, COPD, Headache, Ageing, Food, Respiratory syncytial virus vaccine, III, Conditional sentence, US Foods, Safety, Heart, Diabetes, Stockholm Environment Institute US Center, Infection, Pneumonia, Chronic kidney disease, CDC, Chronic liver disease, Risk, Asthma, ACIP, GSK plc, GSK, Hospital, Pain, Chronic obstructive pulmonary disease, Fatigue, Vaccine, Pharmaceutical industry, Adjuvant

The vaccine elicited an immune response in adults aged 50 to 59 at increased risk for RSV disease due to select underlying medical conditions that was non-inferior to that observed in adults aged 60 and above, meeting the trial’s primary co-endpoint.

Key Points: 
  • The vaccine elicited an immune response in adults aged 50 to 59 at increased risk for RSV disease due to select underlying medical conditions that was non-inferior to that observed in adults aged 60 and above, meeting the trial’s primary co-endpoint.
  • The co-primary endpoint was also met for the broader group of adults aged 50 to 59 also enrolled in the trial.
  • Tony Wood, Chief Scientific Officer, GSK, said: “This trial reinforces our confidence in our RSV vaccine’s ability to help protect adults aged 50 to 59 at increased risk for RSV-LRTD.
  • Immune response in participants aged 50 to 59 with pre-defined stable chronic diseases leading to an increased risk of RSV disease was assessed (n=570).

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)

Retrieved on: 
Tuesday, October 24, 2023
Oncology, FDA, Health, Pharmaceutical, Cardiology, Biotechnology, Allergy, Child, AstraZeneca, PDUFA, Heart, Nursing, History, Prescription Drug User Fee Act, MD, Vaccine, Wheeze, US Foods, Aspirin, Diabetes, University School, Fever, Vaccination, Caregiver, Egg, Immune system, Risk, Safety, Feinberg School of Medicine, Amantadine, Rimantadine, Nasal administration, Patient, Parent, Nose, Pediatrics, Infection

AstraZeneca’s Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for review by the US Food and Drug Administration (FDA).

Key Points: 
  • AstraZeneca’s Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for review by the US Food and Drug Administration (FDA).
  • FLUMIST QUADRIVALENT, which is sprayed into the nose, has extensive data demonstrating comparable effectiveness and acceptable safety relative to other flu vaccines.
  • If approved at that time, FLUMIST QUADRIVALENT is anticipated to be available for self-administration in the US for the 2024/2025 flu season.
  • FLUMIST QUADRIVALENT now has the potential to be the first and only self-administered flu vaccine, which could revolutionize flu vaccination.

Foodservice Market size to grow by USD 13.61 billion from 2022 to 2027, The market is fragmented due to the presence of prominent companies like Compass Group Plc, Aramark and Chick fil A Inc., and many more - Technavio

Retrieved on: 
Wednesday, October 25, 2023
Domino's, Yum! Brands, Food, Sysco, Starbucks, In re Caremark International Inc. Derivative Litigation, MFS, Aramark, Growth, Geography, Employment, FOOD, US Foods, Sid & Marty Krofft Television Productions Inc. v. McDonald's Corp., USD, Papa John's, Compass, Foodservice, Music, Speciality chemicals

The foodservice market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The foodservice market is fragmented owing to the presence of many global and regional companies.
  • Download Sample before buying
    Aramark - The company offers foodservice such as catering, food and beverage management, and facilities management services for various industries.
  • Chick fil A Inc. - The company offers foodservice such as a fast food restaurant chain known for its chicken-based menu.
  • Compass Group Plc - The company offers foodservice such as contract foodservices, including catering, vending, and dining services.

SourceMark Medical Partners with NasaClip to Streamline Nosebleed Treatment

Retrieved on: 
Wednesday, October 25, 2023
MBE, FDA, Minority business enterprise, US Foods, Patient, Partnership, Nosebleed, Birth control, Nursing

FRANKLIN, Tenn. , Oct. 25, 2023 /PRNewswire/ -- SourceMark Medical, a US medical device company and certified Minority Business Enterprise (MBE), announced a supplier partnership today with NasaClip, an easy-to-use nosebleed rescue device available in adult and pediatric sizes.

Key Points: 
  • FRANKLIN, Tenn. , Oct. 25, 2023 /PRNewswire/ -- SourceMark Medical, a US medical device company and certified Minority Business Enterprise (MBE), announced a supplier partnership today with NasaClip, an easy-to-use nosebleed rescue device available in adult and pediatric sizes.
  • "We're thrilled to partner with SourceMark and expand provider access to NasaClip," said Dr. Elizabeth Clayborne, founder and CEO of NasaClip.
  • "NasaClip offers an innovative solution to treat patients with nosebleeds quickly and more effectively with minimal provider intervention," said Dan Blucher, CEO of SourceMark Medical.
  • "We're pleased to partner with NasaClip to improve patient outcomes while cutting nosebleed treatment time and costs."

Darbepoetin Alfa (Aranesp) Global Market Research Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Health, Pharmaceutical, FDA, Sale, Daprodustat, Ageing, National library, Anemia, Food, Epoetin alfa, Bone marrow, Prevalence, Conditional sentence, US Foods, Darbepoetin alfa, GSK plc, Cell, Chronic kidney disease, Growth, Dialysis, Chronic condition, Cancer, Patient, National Library of Medicine classification, Dietary supplement, Pharmaceutical industry

The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The prevalence of chronic diseases is on the rise, and this trend is expected to drive the growth of the darbepoetin alfa market.
  • This substantial increase in the prevalence of chronic diseases is a significant driver of the darbepoetin alfa market.
  • Product innovation is a prominent trend in the darbepoetin alfa market, with major companies adopting new technologies to maintain their market positions.

Median Technologies Reports 2023 Half-year Results and Business Indicators for the Third Quarter of 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Technology, Health, Radiology, Oncology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, Survival, FDA, LP, NMPA, Medical device, Q2, Lung cancer, Medicine, Mortality, US Foods, Chinese, Software, Euronext Growth, Q3, Business, Cave rescue, Survival rate, Patient, EIB, Diagnosis, LCS, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Median

Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).

Key Points: 
  • Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).
  • Commenting on the results, Fredrik Brag, CEO, and co-founder of Median Technologies, said:
    “During the first three quarters of 2023, we made significant strides regarding iBiopsy®.
  • These are key milestones in our roadmap to obtain marketing authorizations for our Software as Medical Device for the US and European markets.
  • Median is poised to play a pivotal role to help significantly reduce the lung cancer mortality rate through more effective diagnosis of early-stage patients.

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer

Retrieved on: 
Saturday, October 21, 2023
FDA, SCLC, Metastasis, Gregorio, ESMO, Food, Pembrolizumab, European Society for Medical Oncology, US Foods, American Society of Clinical Oncology, Research, HIV disease progression rates, Carcinoma, Society, Lurbinectedin, Neoplasm, Ecosystem, Cancer, Congress, Breast cancer, Oncology, Immunotherapy, TACSTD2, Patient, Prognosis, ASCO, Medical imaging, Pharmaceutical industry, Medical device

These results showed that approximately one third of patients with early-stage HER2-positive breast cancer could be treated without chemotherapy and remain free of breast cancer for up to three years after surgery.

Key Points: 
  • These results showed that approximately one third of patients with early-stage HER2-positive breast cancer could be treated without chemotherapy and remain free of breast cancer for up to three years after surgery.
  • A total of 28 patients with SCLC who had not previously received immunotherapy were enrolled in the LUPER trial.
  • In the first of the translational studies presented by MEDSIR at ESMO, we analyzed the expression levels of the Trop-2 protein in tumor samples from patients with HER2-positive early breast cancer.
  • The HER2DX® genomic test may prove to be a valuable tool to guide healthcare professionals and patients in personalizing treatment for HER2-positive early breast cancer.

Frost & Sullivan Recognizes Neuromod Devices with the 2023 New Product Innovation Award for Developing a Robust Solution That Meets Tinnitus Patients' Needs

Retrieved on: 
Wednesday, October 18, 2023
FDA, Frost, Albornoz, Conditional sentence, US Foods, Acquisition, Research, RWE, ROI, Quality of life, Clinical trial, Tinnitus, Overalls, Patient, SAN, Medical device, Dentistry, Pharmaceutical industry

SAN ANTONIO, Oct. 18, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the neuromodulation devices for tinnitus space and, based on its findings, recognizes Neuromod Devices (Neuromod) with the 2023 North American New Product Innovation Award. Neuromod is a medical technology company focused on designing and developing bimodal neuromodulation solutions that address the growing clinical needs of patients with tinnitus.

Key Points: 
  • Neuromod Devices uniquely leverages its sophisticated technology to meet tinnitus patients' dynamic needs and strict global regulatory requirements for medical devices.
  • SAN ANTONIO, Oct. 18, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the neuromodulation devices for tinnitus space and, based on its findings, recognizes Neuromod Devices (Neuromod) with the 2023 North American New Product Innovation Award.
  • Neuromod is a medical technology company focused on designing and developing bimodal neuromodulation solutions that address the growing clinical needs of patients with tinnitus.
  • Neuromod has delivered a groundbreaking medical device and services that support healthcare professionals to achieve exceptional clinical outcomes for their tinnitus patients.